That was all resectable, though the phase I NEJM in R/M has ~50% ORR. Not sure I see the difference in outcomes between lancet oncology follow up paper, admittedly with only 18 mo follow up and the TROG surg+RT data. But as usual med oncs out there doing whatever based on phase II data, never mind the 11% that didn't make it to surgery/ progressed to unresectable.While not standard of care, libtayo can be very effective in skin cancer. NEJM phase two study showed a 50% pathCR rate in unresectable disease.